Regulation & Policy Industry Analysis
Buy the information you need on Pharmaceutical Regulation & Policy. Our catalogue of reports includes specific information on Pharma Compliance, Patent Protection and Drug Registration.
previous
| Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics (CTP00109) The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies. The report provides a detailed... | May 2012 | £1,700 |
| Regulatory Intelligence on Medical Device Recalls (GBI00386) Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for RecallRegulatory Intelligence on Medical Device Recalls - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall Summary GBI Research report, "Regulatory Intelligence on... | Apr 2012 | £2,210 |
| Pricing and Reimbursement in Generics (GBI00381) European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under PressurePricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, has released its latest research... | Apr 2012 | £2,210 |
| Pricing and Reimbursement in Russia (GBI00373) Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies ProgramSummary GBI Research, the leading business intelligence provider, has released its latest research 'Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's... | Apr 2012 | £2,210 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: India (IMS00204) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Hungary (IMS00203) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Mexico (IMS00199) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Poland (IMS00202) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Denmark (IMS00219) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Norway (IMS00201) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Turkey (IMS00192) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Brazil (IMS00215) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £420 |
| Pricing and Reimbursement of The Healthcare System in India (GBI00359) Low Levels of Drug Reimbursement Lead to a High out-of-Pocket ExpenditurePricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure Summary GBI Research, the leading business intelligence provider, has released its... | Mar 2012 | £2,210 |
| New Thinking in Patient Adherence (FWD00081) Patient non-adherence is estimated to represent $290 billion per year in avoidable medical expenses in the United States alone. Consumers' motivations for non-compliance are complex; up to 80% of people... | Mar 2012 | £495 |
| Healthcare, Regulatory and Reimbursement Landscape - Germany (GDA26475) Healthcare, Regulatory and Reimbursement Landscape - Germany Summary GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Germany". The report is an essential source of... | Feb 2012 | £2,520 |
| Healthcare, Regulatory and Reimbursement Landscape - UK (GDA26468) Healthcare, Regulatory and Reimbursement Landscape - UK Summary GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - UK". The report is an essential source of... | Feb 2012 | £2,520 |
| Healthcare, Regulatory and Reimbursement Landscape - Spain (GDA26474) Healthcare, Regulatory and Reimbursement Landscape - Spain Summary GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Spain". The report is an essential source of... | Feb 2012 | £2,520 |
| Healthcare, Regulatory and Reimbursement Landscape - US (GDA26477) Healthcare, Regulatory and Reimbursement Landscape - US Summary Industry analysis specialist GlobalData, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - US". The report is an essential source of information... | Feb 2012 | £2,520 |
| Tiered Pricing Strategies in Emerging Markets (FWD00074) For the pharmaceutical industry, emerging markets are dynamic, full of potential and offer solid growth at a time when established markets are contracting. But they also pose a significant problem:... | Feb 2012 | £495 |
| Pricing and Reimbursement in the US (GBI00327) Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic DrugsGBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from... | Feb 2012 | £2,210 |
| Healthcare, Regulatory and Reimbursement Landscape - Italy (GDA26476) Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of... | Jan 2012 | £2,520 |
| Healthcare, Regulatory and Reimbursement Landscape - Japan (GDA26483) Healthcare, Regulatory and Reimbursement Landscape - Japan Summary GlobalData, the industry analysis specialist, has released its report, "Healthcare, Regulatory and Reimbursement Landscape - Japan". The report is an essential source of information... | Jan 2012 | £2,520 |
| Academic Detailing: Pharma Fights Back (FWD00073) Ever since it was introduced three decades ago, academic detailing-which now increasingly uses pharma's sales techniques to educate physicians-has posed a difficult issue for the industry. Governed by a different... | Jan 2012 | £535 |
| China chinese patent drug processing industry (RFC01310) 2012China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese investments; to import into China... | Jan 2012 | £2,525 |
| Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis (FWD00075) Public healthcare costs are rising. Governments need to get them under control. In Europe, that means the systematic use of health technology assessments (HTA) and reference pricing. The US, on... | Jan 2012 | £515 |
